About
Titles
Research Associate, Radiology
Biography
Eliot Funai graduated from the University of Maryland, Baltimore County, and previously worked at Johns Hopkins University before coming to Yale. His work as a clinical research coordinator is to develop and oversee the management and execution of clinical trials, primarily concerning locoregional therapies for treating liver cancers. His experience is with investigator initiated studies, industry and NIH-funded trials, and cooperative group studies.
Departments & Organizations
- Radiology & Biomedical Imaging
- Yale Interventional Oncology Research Lab
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Eliot Funai's published research.
Julius Chapiro, MD/PhD
Todd Schlachter, MD
Fabian Max Laage Gaupp, MD
Juan Carlos Perez Lozada, MD
Michal Kulon, MD
Publications
2020
Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastasesLipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Translational Oncology 2020, 13: 100742. PMID: 32092672, PMCID: PMC7036424, DOI: 10.1016/j.tranon.2020.01.003.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Contacts
Email